Elevance Health reaffirms FY2025 EPS guidance of $24.70 ($30.00 adj.) and 90.0% benefit expense ratio

Elevance Health, Inc.

Full-year 2025 GAAP EPS expected ~$24.70, including ~$5.30/sh net unfavorable items.
Adjusted EPS guidance unchanged at ~$30.00 per diluted share.
Full-year 2025 benefit expense ratio reaffirmed at approximately 90.0%.
Reaffirmation reflects current view on market conditions, operational performance, and regulatory landscape.
Guidance does not include adjustment items beyond those reported in Q3 2025 earnings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.